Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
-
Shabnam Shokouhi
,
Sarah Bray
,
Salar Bakhtiyari
,
Kourosh Sayehmiri
,
Kamran Alimoghadam
,
Ardeshir Ghavamzadeh
Abstract
Background: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a curative treatment option for many patients with Acute Myeloid Leukemia (AML); however, it can lead to complications of Graft-Versus-Host-Disease (GVHD) which can affect the quality of life and overall survival. The aim of this study was to assess the effects of both acute and chronic GVHD on survival rate in patients with AML who received HSCT.
Subjects and Methods: In a longitudinal study, 587 patients with AML who underwent bone marrow transplantation in Tehran-Iran between1991 and 2011 were recruited. All patient records were analyzed for the occurrence of adverse events including acute and chronic GVHD and leukemia relapse. Data were analyzed using Log-rank, Kaplan-Meier, Univariate and Multivariate Cox Regression models.
Results: The five-year overall survival (OS) was found to be 71.9% (95% CI: 67.40-76.41). Also there was a significant relationship between cGVHD and OS (P=0.001, HR = 0.476, 95%). Hazard of death in these patients was less than those who did not experience an occurrence of cGVHD and aGVHD (HR= 0.629, P= 0.078). A significant relationship between cGVHD and relapse was observed (P< 0.001) indicating that patients who developed cGVHD experienced a better survival rate. A significant relationship was also found between overall survival and aGVHD grade (P< 0.001). Hazard of death (HD) for cGVHD and relapse variables were estimated to be 0.554 and 3.869.
Discussion: This study is one of the largest studies (regarding the number of participants) done to date in the Middle East with quite a long duration (20 years). cGVHD appears to have a positive influence on survival rate in patients with AML who received HSCT. It is recommended that further studies investigate the underlying reason or mechanisms behind this.
Copelan EA. Hematopoietic Stem-Cell Transplantation. The New England Journal of Medicine. 2006; 354:1813- 26.
Lee SJ, Vogelsang G, Flowers MED. Chronic Graft- versus-Host Disease. Biology of Blood and Marrow Transplantation. 2003; 9:215-33.
Messerer D, Engel J, Hasford J, et al. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica.2008; 93:826-33.
Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. American Journal of Medicine. 1980;69:204-17.
Harris AC, Kitko CL, Couriel DR, et al. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica. 2013; 98:179-84.
Kataoka I, Kami M, Takahashi S, et al. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. Bone Marrow Transplantation. 2004; 34: 711-9.
Ishiyama K, Takami A, Shiobara S, et al. Graft-versus- leukemia effect of allogeneic stem cell transplantation; a Japanese single center study. Haematologica. 2004; 89: 887-9.
Ringden O, Shrestha S, da Silva GT, et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant. 2012; 47: 831-7.
Lee JH, Choi SJ, Seol M, et al. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. Haematologica. 2005; 90: 1380-8.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-56.
Neilly IJ, Ogston M, Bennett B, et al. High grade non- Hodgkins lymphoma in the elderly--12 year experience in the Grampian Region of Scotland. Hematol Oncol. 1995; 13: 99-106.
Nannya Y, Kanda Y, Oshima K, et al. Prognostic factors in elderly patients with acute myelogenous leukemia: a single center study in Japan. Leuk Lymphoma. 2002; 43:83-7.
Johnson PR, Hunt LP, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol. 1993; 85: 300-6.
Cox DR. Regression models and life tables. Journal of the Royal Statistical Society, Series B 1972.34:187–220.
Kaplan E, Meier P. Non parametric estimation from incomplete observations. Journal of the American Statistical Relationship. 1958; 53:457-81.
Klien JP, Moeschberger ML. Survival analysis techniques for censored and truncated data. New York: Springer, 1997.
Hashmi K, Khan B, Ahmed P, et al. Graft Versus HostDisease in Allogeneic Stem Cell Transplantation - 3 ½ Years Experience. The Journal of the Pakistan Medical Relationship. 2005; 55: 423-7.
Sayehmiri K, Eshraghian MR, Mohammad K, et al. Predictive Factors of Survival Time after Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia Patients who Received Allogeneic BMT from Matched Sibling Donors Using Generalized Gamma Models. International Journal of Hematology Oncology and Stem Cell Research. 2009;3:21-6.
Sayehmiri K, Alimoghaddan K, Ghavamzadeh A. Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation. International Journal of Hematology Oncology and Stem Cell Research. 2010; 4:19- 28.
Akpek G, Zahurak M.L , Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001; 97: 1219- 26.
Kataoka I, Kami M, Takahashi S, et al. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. Bone Marrow Transplant. 2004; 34:711-9.
Cavet J, Dickinson AM, Norden J, et al. Interferon- gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594-600.
Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990; 75: 2459-64.
Gustafsson-Jernberg A, Remberger M, Ringdén O, et al. Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplantation. 2003; 31:175-81.
Kim H-J, Min W-S, Eom K-S, et al. Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia. Bone Marrow Transplantation. 2007; 40: 1069-74.
Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: relationship with treatment- related mortality and relapse. Blood. 2002; 100: 406-14.
Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003; 17: 841-8.
Horowitz MM, Gale RP, Sondel PM, et al. Graft- versus-leukemia reactions after bone marrow transplantation. Blood.1990; 75:555-62.
Lee S, Cho B-S, Kim S-Y, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation. 2007; 13: 1083-94.
Toze CL, Galal A, Barnett MJ, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graftversus- leukemia effect associated with graft-versus-host disease. Bone Marrow Transplantation. 2005; 36: 825-30.
Ringdén O, Pavletic SZ, Anasetti C, et al. The graft- versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009; 113: 3110-8.
Baron F, Labopin M, Niederwieser D, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012; 26:2462-8.
Mitus AJ, Miller KB, Schenkein DP, et al. Improved survival for patients with acute myelogenous leukemia. Journal of Clinical Oncology. 1995; 13: 560-9.
Maynadié M, Girodon F, Manivet-Janoray I, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica. 2011; 96:55-61.
Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood.2013; 121: 219-25.
| Files | ||
| Issue | Vol 9, No 3 (2015) | |
| Section | Articles | |
| Keywords | ||
| Acute Myeloid Leukemia HSCT Survival rate aGVHD cGVHD | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
